362 filings
Page 13 of 19
8-K
m8lwjyao3ivmb98uh
9 May 19
PhaseBio Reports First Quarter 2019 Financial and Business Results
4:05pm
SC 13G
p5va wachah3
22 Apr 19
PhaseBio Pharmaceuticals Inc
1:41pm
424B4
oo2mv4fz569
12 Apr 19
Prospectus supplement with pricing info
4:32pm
S-1MEF
71le4 obb
11 Apr 19
Registration of additional securities for an S-1
9:09pm
EFFECT
ku3ur
11 Apr 19
Notice of effectiveness
12:00am
8-K
8lds376ngrxh1ccy1
10 Apr 19
Regulation FD Disclosure
8:00am
CORRESP
mh2edx85e7m 7f3g
10 Apr 19
Correspondence with SEC
12:00am
CORRESP
h3dz9igktneuodc2s9m
10 Apr 19
Correspondence with SEC
12:00am
8-K
hx0622ufa9afw8cm1j4c
9 Apr 19
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
8:01am
CORRESP
tnaeu3ryge5x2o b0
9 Apr 19
Correspondence with SEC
12:00am
CORRESP
elvaj57tzdf56g4t ch
9 Apr 19
Correspondence with SEC
12:00am
8-K
829yon24t0rpgwo9xg5
8 Apr 19
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:25pm
UPLOAD
cx7ajo14b9w0exk gp
8 Apr 19
Letter from SEC
12:00am
DEF 14A
3cvb4is
5 Apr 19
Definitive proxy
4:05pm
8-K
pc8gdc quorwa
4 Apr 19
Entry into a Material Definitive Agreement
4:05pm
DRS
bxb6r9d27ee
29 Mar 19
Draft registration statement
12:00am
10-K
maclv
26 Mar 19
Annual report
4:45pm
S-8
gx3qjj 9e
26 Mar 19
Registration of securities for employees
4:10pm